 |
PDBsum entry 2bvq
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Glycoprotein/peptide
|
PDB id
|
|
|
|
2bvq
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Structures of three HIV-1 hla-B5703-Peptide complexes and identification of related hlas potentially associated with long-Term nonprogression.
|
 |
|
Authors
|
 |
G.B.Stewart-Jones,
G.Gillespie,
I.M.Overton,
R.Kaul,
P.Roche,
A.J.Mcmichael,
S.Rowland-Jones,
E.Y.Jones.
|
 |
|
Ref.
|
 |
J Immunol, 2005,
175,
2459-2468.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Long-term nonprogression during acute HIV infection has been strongly associated
with HLA-B*5701 or HLA-B*5703. In this study, we present the high resolution
crystal structures of HLA-B*5703 complexes with three HIV-1 epitopes: ISPRTLNAW
(ISP), KAFSPEVIPMF (KAF-11), and KAFSPEVI (KAF-8). These reveal peptide
anchoring at position 2 and their C termini. The different peptide lengths and
primary sequences are accommodated by variation in the specific contacts made to
the HLA-B*5703, flexibility in water structure, and conformational adjustment of
side chains within the peptide-binding groove. The peptides adopt markedly
different conformations, and trap variable numbers of water molecules, near a
cluster of tyrosine side chains located in the central region of the
peptide-binding groove. The KAF-11 epitope completely encompasses the shorter
KAF-8 epitope but the peptides are presented in different conformations; the
KAF-11 peptide arches out of the peptide-binding groove, exposing a significant
main chain surface area. Bioinformatic analysis of the MHC side chains observed
to contribute to the peptide anchor specificity, and other specific peptide
contacts, reveals HLA alleles associated with long-term nonprogression and a
number of related HLA alleles that may share overlapping peptide repertoires
with HLA-B*5703 and thus may display a similar capacity for efficient immune
control of HIV-1 infection.
|
 |
|
|
|
|
 |